Diagnostic Performance of Plasma DNA Methylation Profiles in Lung Cancer, Pulmonary Fibrosis and COPD  by Wielscher, Matthias et al.
EBioMedicine 2 (2015) 929–936
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comOriginal ArticleDiagnostic Performance of Plasma DNA Methylation Proﬁles in Lung
Cancer, Pulmonary Fibrosis and COPDMatthiasWielscher a, KlemensVierlinger a, Ulrike Kegler a, Rolf Ziesche b, Andrea Gsur c, AndreasWeinhäusel a,⁎
a AIT — Austrian Institute of Technology, Health & Environment Department, Molecular Diagnostics Unit, Muthgasse 11/2, 1190 Vienna, Austria
b Medical University of Vienna, Clinical Department for Pulmonology, Spitalgasse 23, 1090 Vienna, Austria
c Medical University of Vienna, Institute of Cancer Research, Borschkegasse 8A, 1090 Vienna, AustriaAbbreviations:AUC, area under curve; cfDNA, cell-free
pulmonary disease; Ct-value, cycle threshold; HP, hypers
terstitial lung disease, IPF, idiopathic pulmonary ﬁbrosis;
MSRE, methyl sensitive restriction enzyme; NSIP, non-sp
ROC, receiver operating characteristics; UIP, usual intersti
⁎ Corresponding author at: AIT Austrian Institute of Tech
1190 Vienna, Austria.
E-mail address: Andreas.Weinhaeusel@ait.ac.at (A. We
http://dx.doi.org/10.1016/j.ebiom.2015.06.025
2352-3964/© 2015 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 20 May 2015
Received in revised form 23 June 2015
Accepted 26 June 2015
Available online 2 July 2015
Keywords:
Liquid biopsy
methyl-sensitive restriction enzyme
multiplex PCR
Biomarker
PAX9
HOXD10Disease-speciﬁc alterations of the cell-free DNA methylation status are frequently found in serum samples and
are currently considered to be suitable biomarkers.
Candidate markers were identiﬁed by bisulﬁte conversion-based genome-wide methylation screening of lung
tissue from lung cancer, ﬁbrotic ILD, and COPD. cfDNA from 400 μl serum (n= 204) served to test the diagnostic
performance of these markers. Following methylation-sensitive restriction enzyme digestion and enrichment of
methylated DNA via targeted ampliﬁcation (multiplexed MSRE enrichment), a total of 96 markers were
addressed by highly parallel qPCR.
Lung cancer was efﬁciently separated from non-cancer and controls with a sensitivity of 87.8%, (95%CI:
0.67–0.97) and speciﬁcity 90.2%, (95%CI: 0.65–0.98). Cancer was distinguished from ILD with a speciﬁcity of
88%, (95%CI: 0.57–1), and COPD from cancer with a speciﬁcity of 88% (95%CI: 0.64–0.97). Separation of ILD
from COPD and controls was possible with a sensitivity of 63.1% (95%CI: 0.4–0.78) and a speciﬁcity of 70%
(95%CI: 0.54–0.81). The results were conﬁrmed using an independent sample set (n = 46) by use of the four
top markers discovered in the study (HOXD10, PAX9, PTPRN2, and STAG3) yielding an AUC of 0.85 (95%CI:
0.72–0.95).
This techniquewas capable of distinguishing interrelated complex pulmonary diseases suggesting that multiplexed
MSRE enrichment might be useful for simple and reliable diagnosis of diverse multifactorial disease states.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
DNA methylation analysis of cell-free blood samples has a substan-
tial potential to serve as a minimally invasive tool for early diagnosis
and clinical monitoring of diseases with considerable heterogeneity
Mouliere and Rosenfeld, 2015, in particular cancer and cancer-related
diseases. Important lung pathologies, such as chronic obstructive lung
disease (COPD) and ﬁbrotic interstitial lung diseases (ILD) are associat-
ed with a signiﬁcantly increased risk of cancer development Tomassetti
et al., 2015 rendering diagnosis andmonitoring of pulmonary lesions in
these states is a highly challenging task. Usually, both diagnosis and
monitoring of these diseases require repeated sampling of pulmonary
tissue. This procedure harbors considerable risks for the patients FiblaDNA;COPD, chronic obstructive
ensitivity pneumonitis; ILD, in-
MSP, methyl speciﬁc priming;
eciﬁc interstitial pneumonitis;
tial pneumonia.
nologyGmbH,Muthgasse 11/2,
inhäusel).
. This is an open access article underet al., 2012. As a result, identiﬁcation of pulmonary lesions frequently
relies on advanced pulmonary imaging, such as computed tomography
scans Lederlin et al., 2013. This approach, however, yields increasing
numbers of pulmonary lesions of questionable clinical value Fang
et al., 2014 adding to diagnostic insecurity.
A non-invasive approach allowing for a reliable differentiation
between lung cancer and lung cancer-associated diseases like ILD and
COPD is an unmet diagnostic issue. In this proof of principle study, we
thus asked whether these three associated disease states could be
discerned by DNA methylation analysis in cell free plasma samples.
Analysis of DNAmethylation was chosen for three reasons: (a) the spe-
ciﬁc features of cancerous tissue are equally well represented by chang-
es of DNA methylation and DNA point mutation Li et al., 2009; Thierry
et al., 2010; Diehl et al., 2005; (b) while point mutations are randomly
distributed across a genetic locus, DNA methylation is clustered in
speciﬁc regulatory regions Brock et al., 2008; Esteller, 2008; and
(c) changes of methylation have been identiﬁed for all three clinical
states Bruse et al., 2014; Sanders et al., 2012; Qiu et al., 2012.
Most detectionmethods analyzingDNAmethylation rely onbisulﬁte
conversion of DNA allowing for the detection of single CpGswhile at the
same time impeding further PCR ampliﬁcation and thus, analysis ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
930 M. Wielscher et al. / EBioMedicine 2 (2015) 929–936additional regions of interest. This limits detection of methyl-speciﬁc
priming (MSP) to 10 simultaneous performed reactions Sanders et al.,
2012 and less than 5 for MethyLight™, respectively Fackler et al.,
2014; Olkhov-Mitsel et al., 2014. In order to address as many methyla-
tion changes as possible in limited clinical samples, we chose high
multiplexing methyl-sensitive restriction enzyme (MSRE) qPCR for
stabilization of prediction and diagnostic accuracy Weinhaeusel et al.,
2008; Melnikov et al., 2005 which allowed for the simultaneous
performance of 96 qPCRs in cfDNA from 400 μl plasma.
OurmultiplexedMSRE enrichment approach enabled us to effectively
differentiate between lung cancer, pulmonary ﬁbrosis, and healthy
subjects allowing for the formulation of a four-marker model capable
of distinguishing lung cancer from controls, ﬁbrotic ILD, and COPD.2. Methods
2.1. Study Design and Patients
A total of 250 serum or plasma samples derived from COPD, ILD, and
lung cancer patients were analyzed (Table 1). Cancer Cases were
recruited between 1996 and 2006 from the Pulmological Centers,
Baumgartner Hoehe, Vienna and Grimmenstein-Hochegg, Lower
Austria. Additional, population-based controls were selected from the
ongoing colorectal cancer screening project “Burgenland PREvention
trial of colorectal cancer Disease with ImmunologiCal Testing” (B-PRE-
DICT). Interstitial lung disease (ILD) included of usual interstitial
pneumonia (UIP) of early, limited from, and of progressive, advanced
form, as well as of non-speciﬁc interstitial pneumonitis (NSIP) patients.
Further hypersensitivity pneumonitis, which is due to its durance
categorized into of an acute and chronic from, was also included in the
group of ILD patients. All ILD and COPD sera were collected from 2008
to 2012 at the Medical University of Vienna. The study was approved
by the concordant responsible ethics committee of Lower Austria (No:
GS4-EK-1/121-2005), the Burgenland (No: 33/2010) and the Medical
University of Vienna (No: 533/2004; No: 013/2009) and was carried
out in compliance with the Helsinki Declaration. Patients gave a written
informed consent.Table 1
Clinical Characteristics of patient serum/plasma samples.
250 samples were analyzed. 204 within the original set and 46 within the PoP (proof of princ
indicates themean age of each patient group. S indicates serum; P Plasma; female reﬂects the p
tern of ILD was not available for 12 ﬁbrotic ILD patients and cancer staging information was no
cinoma; SqCC: squamous cell carcinoma, SCLC: small cell lung cancer, LCLC: large cell lung can
Original set (n = 204)
Patients Type Female
Healthy N = 61 (29.9%)
Healthy n = 27 (13.2%) S&P 27.5%
COPD 0 n = 34 (16.6%) S 26.5%
Lung cancer N = 33 (16.1%)
TNM I&II n = 9 (4.4%) P 44.4%
TNM III&IV n = 15 (7.3%) P 40%
Lung cancer N = 33 (16.1%)
AdenoCa n = 11 (5.4%) P 54.5%
SqCC n = 8 (3.9%) P 12.5%
SCLC n = 7 (3.4%) P 57.1%
LCLC n = 7 (3.4%) P 0%
COPD N = 42 (20.5%)
GOLD I–II n = 31 (15.1%) S 19.4%
GOLD III–IV n = 11 (5.4%) S 18.2%
ILD N = 68 (33.3%)
IPF, limited UIP n = 15 (7.3%) S 20%
IPF, advanced UIP n = 10 (4.9%) S 50%
NSIP n = 11 (5.4%) S 27.3%
HP n = 22 (10.7%) S 27.3%2.2. Experimental Procedures
The 204 serum samples were randomized and split into three parts
each one underwent separate multiplexed MSRE enrichment and
Biomark qPCR read out. 46 samples from proof of principal (POP) set
were processed separately. Technical replicates of samples as well as
negative controls were introduced by the time of cell free DNA (cfDNA)
isolation and randomly distributed to the three experimental blocks.
Standard curves, which also served as ampliﬁcation control, as well as
additional negative controls, were introduced before multiplexed en-
richment. cfDNA was isolated out of 400 μl patients' serum using Roche
High pure template preparation kit (Roche) with a modiﬁed isolation
protocol published previously Wielscher et al., 2011. In a volume of
12 μl cfDNA was digested with four methylsensitive restriction enzymes
(MSRE) namely HpaII (ThermoFisher), Hin6I (ThermoFisher), AciI
(NewEnglandBiolabs) and HpyCHIV4 (NewEnglandBiolabs). 10 μl of
the MSRE digestion reaction was subjected to a multiplexed pre-
ampliﬁcation. Preampliﬁcation reaction was performed in a volume of
20 μl using 96 primer pairs per sample. 19 cycles of preampliﬁcation
were performed. qPCR detection, consisting of 96 single qPCR reactions
per sample, was performed on a BioMark™ HD Reader (Fluidigm). For
detailed information on all experimental procedures and patients, see
study ﬂow ﬁgure (Fig. 1) and in supplemental material pp 1–3.2.3. Statistical Analysis
All computations and statistical analyses were performed using R
3.0.2 Team RC, 2005 and Bioconductor 2.13 (http://www.bioconductor.
org) Gentleman et al., 2004. Binominal classiﬁcation comparing each dis-
ease group to healthy controls was performed on basis of linear models
using lasso penalized logistic regression taken from the R package
glmnet Anon, 2008. Differential multinomial classiﬁcations were
performed using boosted trees method Friedman, 2001. Detailed infor-
mation on Ct value preprocessing and data normalization, outlier
identiﬁcation and handling, prediction and resampling approach, the de-
termination of optimal cutoffs, and simulation of automated assignment
of clinical samples are given in supplemental material pp 3–7.iple) set. Type indicates whether a serum or plasma was available from the patients. Age
ortion of female patients in percent. Information on the characteristic histopathologic pat-
t available for 7 sera of the original set and 3 sera of the PoP set. AdenoCa, lung adenocar-
cer.
PoP set (n = 46)
Age Patients Type Female Age
N = 23 (50%)
57.5 n = 23 (50%) P 17.4% 63.3
48 –
N = 23 (50%)
65.6 n = 8 (17.4%) P 37.5% 60.4
65 n = 12 (26%) P 58.3% 63.7
N = 23 (50%)
63.9 n = 9 (19.5%) P 77.7% 58.3
60.1 n = 4 (8.6%) P 0% 65.3
70.1 n = 6 (13%) P 66.6% 69.3
70.7 n = 4 (8.7%) P 0% 58.2
–
52.6 –
62.4 –
–
65.3 –
56.6 –
68 –
51.7 –
Fig. 1. Study ﬂow diagram. The discovery was performed on bisulﬁte converted DNA de-
rived from lung tissue of lung cancer patients, ﬁbrotic ILD, COPD patients and healthy con-
trols. Candidate markers revealed by Illumina 450K arrays were validated on the same
samplematerial via MSRE digestion based qPCR. The best performing assays in this proce-
dure were then used for minimal invasive cfDNA methylation detection. Thus a 4-gene
model could be established, which was validated on an independent sample set of 46
patients.
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3.1. From Illumina 450 K Probe to MSRE-qPCR Assay
We ﬁrst employed Illumina's 450K arrays for the detection of
methylation signatures speciﬁc for lung cancer, ﬁbrotic ILD and COPD
in pulmonary tissue (GSE 63704). For the biomarker selection we pur-
sued an exploratory data analysis approach. First a moderated t-test
was performed for every disease group, followed by inspection of
P-values, fold changes and boxplots as well as ROC-curve analysis
indicating the ability of each marker to distinguish between inspected
disease class and healthy or all remaining classes. In sum, 251 qPCR
assays were designed to meet the genomic vicinity of the selected
Illumina probes (Supplemental Fig. S2, Supplemental Table S1 & S2).
Samples were validated in lung tissue achieving a validation rate of
65.7% (Supplemental Table S3). Themethylation signature of the select-
ed probes was rated as valid if qPCR delta Ct values and micro array
beta-values showed a signiﬁcant correlation (P b 0.05) (Supplemental
Table S3).
The best selection criteria of probes for qPCR validation were (in
order of efﬁcacy): fold change of methylation beta-values from
microarray data, number of MSRE cut sites, ROC curve and P values
frommicroarray data (Supplemental Figs. S2& S3). A strong enrichment
of PCR assays located on a CpG island was observed (Supplemental
Fig. S4).
As described in detail in the Method section and in Fig. 1, 92 markers
out of 222 data producing qPCR assays aftermultiplex PCR (Supplemental
Fig. S2) were selected for cfDNA methylation assessment, and 63 assays
passed the quality control (Fig. 1). Detailed information on all qPCR assays
is given in Supplemental Table S1–S3.
3.2. cfDNA Amounts in Patient Sera
All samples representing cancer, idiopathic pulmonary ﬁbrosis (IPF;
limited and advanced UIP), ﬁbrotic non-speciﬁc interstitial pneumonia
(NSIP), and COPD (GOLD grade 3) showed a signiﬁcant differenceregarding cfDNA concentrations compared to healthy controls (Fig. 2A
and Supplemental Table S4). No difference was detected between
serum and plasma samples (Supplemental Fig. S5). As previously
shown, the highest amount of cfDNA was observed in lung cancer pa-
tients. cfDNA amounts in cancer increased by factor 2.8 to 35.6 ng/ml
(95%CI: 29.05–43.23) for TNM stages I and II and 47.4 ng/ml (95%CI:
30.79–63.28), respectively, for TNM stages III and IV when compared
to normal.
3.3. cfDNA Reveals Disease Speciﬁc Methylation Signature
To increase efﬁcacy of cfDNAmethylation analysis in patient plasma,
we used multiplexed methyl sensitive restriction enzyme (MSRE)
enrichment leaving the methylated DNA fraction intact (Fig. 2B),
while fragmenting unmethylated cfDNA. With this approach, it was
possible to analyze a total of 204 serum and plasma samples (lung can-
cer, n = 33; ﬁbrotic ILD, n = 68; COPD, n = 42; healthy, n = 61;
Table 1). Reproducibility was further addressed by analysis of 16
randomly chosen replicates demonstrating amean Spearman's rank cor-
relation coefﬁcient of 0.69 (95%CI: 0.63–0.74) (Supplemental Fig. S8).
On the basis of differential methylation observed in patient samples,
a penalized logistic regression was performed. qPCR Ct values of the 63
candidate loci and the cfDNA amounts were used to create a prediction
model. Based on the randomly assigned training set (75% of samples),
coefﬁcients were build. Prediction was then performed on the remain-
ing 25% of the samples (test set) (Fig. 2B.). This process was repeated
200 times and the resulting probabilities of sample class membership
were averaged. To estimate the diagnostic value of the methylation
markers tested, each disease group was compared to healthy controls
(Fig. 2C). ROC analysis revealed an area under curve (AUC) of 0.91
(95%CI: 0.84–0.96) for lung cancer, 0.815 (95%CI: 0.73–0.88) for ILD,
0.73 (95%CI: 0.62–0.83) for COPD, and 0.828 (95%CI: 0.76–0.89) for all
diseases versus healthy controls.
3.4. Differential Diagnosis of Lung Cancer, ILD and COPD
In order to achieve a stringent analytical approach capable of com-
plying with the diagnostic needs, we performed simultaneous analysis
of cfDNAmethylation for all disease groups based on highlymultiplexed
MSRE enrichment. L1 regression, support vector machines or random
forest was compared with regression tree-based gradient boosting for
all 63 candidate loci and cfDNA amounts. The latter one turned out to
be the most effective one for sample classiﬁcation.
For differential diagnosis, the same resampling strategy was used
(Fig. 2B). As depicted in Fig. 3A, three prediction roundswere performed
to classify each sample of the entire sample pool. The ﬁrst prediction
round separated cancer from non-cancer cases in 90.6% (Fig. 3A and
B). In the second round, cancer cases were subdivided into TNM classes
I and II or TNM classes III and IV (Supplemental Fig. S9). The third
prediction round distinguished between healthy controls, COPD, and
ILD cases (Fig. 3A, 3C).
Introduction of cutoff values for each diagnostic group was deter-
mined by group membership probabilities obtained from gradient
boosting classiﬁcation (Fig. 3B, C). Signiﬁcance of differentially methyl-
ated loci is given as relative variable importance (Fig. 3B, C) reﬂecting
the number of decisions from gradient boosting classiﬁcation made on
basis of each candidate loci. Nonetheless, correlating markers, such as
CACNA1B, ZIC1, DLX1, or SIM1, being potentially equally discriminative
as the top markers PAX9, HOXD10, PTPRN2, and STAG3 given in Fig. 3B
and C, do not appear in the ﬁgure as a result of the model building pro-
cess. Detailed information of all assays including P-values und fold
changes is given in Supplemental Table S5 & S6. The four top markers
found by multiplexed MSRE enrichment strategy were HOXD10, PAX9,
PTPRN2, and STAG 3. HOXD10 and STAG3were capable of discriminating
lung cancer, ILD and COPD from healthy (Fig. 4B), while PAX9 and
PTPRN2 demonstrated a strong speciﬁcity for lung cancer (Fig. 4A).
Fig. 2. Overview of cfDNA analysis. (A) Log2-transformed amount of cfDNA per ml serum/plasma is shown. Error bars indicate standard deviation of the mean. (B) The colored strings
represent the cfDNAs. Those with CH3 groups represent methylated DNA, the purple strings demonstrate cfDNA from healthy tissue (purple) and lung cancer (red), respectively.
cfDNA processingworkﬂow: Each reaction was based on one serum sample (400 μl). During enzymatic digestion, methylation protected themethylated cfDNA stringswhich then served
as templates for targeted ampliﬁcation (Pre-amp). Onemultiplexedpreampliﬁcationwas performedper sample using 96primerpairs as indicated bydifferent colors. Ampliﬁcation results
are shown in black color. Speciﬁc methylationmarkers were detected by individual qPCR reactions. The lower panel shows the prediction and resampling approach (seeMethod section).
(C) Fisher discriminant analysis was performed using the top 30 markers subsequently, the data were projected to 2 most informative projection directions (discriminant scores). The
plot shows separation of patient samples based on the transformed data, which may be interpreted similar to a Principal Component Analysis. (D) ROC-curve analysis shows quality of
separation of each analyzed disease versus healthy controls.
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The ultimate goal of our approach was an automated assignment of
clinical samples to predeﬁned diagnostic entities. Using all methylation
markers detected in our analysis, we addressed their predictive power
by an adjusted resampling strategy dividing all 204 plasma samples
into 10 partitions. Each partition served as an unknown test sample
during 10 rounds of automated clinical assignment (Supplemental Fig.
S1). The synopsis of the classiﬁcation is given in Fig. 5A demonstrating
(a) the effectiveness of highly multiplexed MSRE enrichment for
discrimination of the disease states tested (lung cancer, ILD, COPD and
healthy), and (b) the overlaps between these clinical entities. Using
cutoff-values derived from the corresponding training sets, it was possi-
ble to identify samples from cancer patients in 84.8% (28 of 33 cases).
Patient samples derived from ILD patients were detected in 48.5% (33
of 68 cases), whereas COPD patients were discovered in 45.2% (19 of
42 cases). Healthy controls were identiﬁed in 50.8% (31 of 61 controls).
Speciﬁcitywas highest for diagnosis of lung cancer as depicted in Fig. 5A
and B. A typical example for lung cancer (red) is shown in Fig. 5B dem-
onstrating both the inter- and intra-individual discriminative power of
multiplexedMSRE enrichment for lung cancer diagnosis. In comparison
to cancer, speciﬁcity was lower for both ILD (blue) and COPD (green)
samples, probably due to the considerable overlap between both
diseases (Fig. 5B, patient 2 and 3). This is conﬁrmed by the number of
double positive predictions (n=48). Discrimination of healthy samples
from both cancer and ILD samples was very effective, whereas samples
representing healthy and COPD demonstrated a large overlap, possiblydue to the fact that in our group of COPD patients, early stage COPD
(GOLD grade 1 and 2) was overrepresented (73.8%).
3.6. Independent Validation of Multiplexed MSRE Enrichment for Cancer
Classiﬁcation
Based on the predictive power of our approach for lung cancer, we
then analyzed 46 new samples (healthy: n = 23; lung cancer: n =
23) comparing the full prediction model based on all methylation
markers with a prediction model using only the 4 top markers by that
addressing quality and stability of our automated prediction procedure
(proof of principle; PoP-set, Table 1). ROC curve analysis showed that
the 4-marker model (Fig. 6A, solid line) outperformed the full 64-
marker model (Fig. 6A, dotted line) yielding an AUC of 0.85 (95%CI:
0.72–0.95) with a sensitivity of 0.97 (95%CI: 0.61–1) and a speciﬁcity
of 0.73 (95%CI: 0.61–0.83). Using this approach, 22 of the 23 cancer
samples were correctly identiﬁed, whereas two healthy cases were
rated as COPD and 8 healthy controls as cancer (Supplemental Fig. S10).
4. Discussion
The goal of our study was to identify methylation biomarkers for
cfDNA that permit an effective discrimination between overlapping
and multifactorial lung diseases, such as cancer, ILD, and COPD
(Table 1). Given the complex and intertwined pathology of these dis-
eases, it is likely that epigenetic mechanisms, such as CpG dinucleotide
methylation, contribute to their clinical phenotypes. Aberrant methyla-
tion has already been demonstrated for diseases like lung cancer,
Fig. 3. Differential diagnosis approach. (A) The classiﬁcation scheme starts with the separation of cancer samples, which are subsequently subdivided into TNMI&II and TNMIII&IV. The
non-cancer samples are classiﬁed into healthy, ﬁbrosis and COPD. This scheme implicates three prediction rounds, with results given in (B) and (C). The result for the separation of cancer
TNMI&II and cancer TNMIII&IV is given in Supplemental Fig. S9. Percent values indicate the correct classiﬁcation rate applying the determined cut off value given in sections B and C for
each disease. (B and C) Bar plots indicate the relative variable importance for eachmodel. The relative variable importance reﬂects the contribution of each variable to the prediction suc-
cess. ROC curves indicate the quality of group separation including the chosen cut off value given as black dot. The rightmost panel summarizes the ROC curve analysis starting with the
values (Area under curve, Sensitivity and Speciﬁcity) derived from conventional ROC curve analysis. The section below, starting with “CutOff”, lists the values gained by the application of
the speciﬁc cut off values. (B) Distinguishes between cancer and residual samples(C) classify residual samples into healthy, ﬁbrotic ILD and COPD.
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Robertson, 2005. Yet, both detection and monitoring of such complex
clinical states remain a considerable challenge Crowley et al., 2013.
This is also true for the group of ﬁbrotic ILD and for COPD, which cur-
rently accounts for 260 million patients worldwide and an annual
death rate comparable to that of cancer Organization WH, 2011. Given
the fact that both diseases show an increased risk of cancer develop-
ment Tomassetti et al., 2015; Koshiol et al., 2009, it is conceivable that
comparable epigenetic regulations will contribute to their pathologies
in spite of existing phenotypical differences.
It is unlikely that a molecular discrimination between these diseases
can be achieved using a singlemarker. Therefore, there is a need for a di-
rected modeling of marker panels Brock et al., 2008; Bruse et al., 2014;
Nikolaidis et al., 2012; Begum et al., 2011 as shown in our approach.
Analysis of DNA methylation in plasma samples is well suited for such
a goal Crowley et al., 2013; Fleischhacker et al., 2013. DNA methylation
analysis largely relies on bisulﬁte conversion of cfDNA. This technique ischaracterized by an unavoidable degradation of DNA and a substantial
loss of sequence complexity resulting in decreased sensitivity and
speciﬁcity during PCR-based biomarker detection Egger et al., 2012. To
overcome these technical limitations, we used a multiplexed MSRE
enrichment strategy allowing for the reduction of unmethylated
background DNA followed by simultaneous ampliﬁcation of 96 targets
(Supplemental Fig. S11).
Prior to any classiﬁcation efforts based on patients DNAmethylation,
the contribution of the cfDNA amount was removed from the data by
delta Ct normalization to be speciﬁc for disease derived methylation
changes (Supplemental Figs. S6 & S7). The elevated cfDNA levels,
however, were included as a separate predictor with in the study.
Such an increase of cfDNA was frequently observed for diverse
cancers Wielscher et al., 2011; Jung et al., 2004; Dawson et al., 2013
and late stage COPD patients Gormally et al., 2004. The presence
of DNA exhibiting disease marks in serum may be due to an interplay
of several mechanisms Schwarzenbach et al., 2011. Necrosis of
Fig. 4. Representative markers for differential diagnosis. Upper panel sections A and B
demonstrate the effect of each variable on class probability. Class probability is given on
the y-axis, while delta Ct-values are shown on the x-axis. Dependence of each predictor
variable is averaged over the distribution of all modeled variables. The upper panel
demonstrates the change of class probability (healthy, cancer, ILD, and COPD) as a function
of Ct-value changes for the 4 top markers identiﬁed. The lower panels display boxplots
of delta Ct-values for each marker. Due to the applied PCR methodology, lower
delta Ct-values indicate increased marker methylation.
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or tissue repair, leads to increased DNA amounts Choi et al., 2005;
Schulte-Hermann et al., 1995 in ﬁbrosis patients and COPD patients
(Fig. 2A). For cancer, additionally, the active release of DNA by cancer
cells may be a reason for increased DNA amounts in patient sera
Stroun and Anker, 2005.
We performed binominal classiﬁcations (case vs. control) based on
logistic regression (using 63 methylation markers plus plasma-cfDNA
concentration as additional predictor) to compare the diagnostic perfor-
mance of our selectedmethylationmarkerswith that of previously pub-
lishedmarkers.We saw the best discriminative powerwhen comparing
cancer to healthy samples yielding an AUC = 0.91 (95%CI: 0.84–0.96)
with a sensitivity of 0.82 (95%CI: 0.61–0.97) and speciﬁcity of 0.89Fig. 5.Results of simulated prospective sample prediction. Simulationwas achieved via an adjus
classiﬁcation results derived from the simulation of prospective samples. The samples arranged
the pie represents the predicted samplememberships in percent. No Diagn. reﬂects 11 samples
below all cut off values. (B) The lower panel shows the classiﬁcation of 4 representative patient
was diagnosedwith COPD GOLDII and patient 4 is a healthy control. The x-axis represents the c
off value to a 100% probability.(95%CI: 0.47–0.98). Comparable accuracy using cfDNA analysis from
serum or plasma samples was previously observed in two studies ad-
dressing cancer vs. healthy (a) via measurement of global hypomethy-
lation by massively parallel bisulﬁte sequencing for detection of lung,
breast and nasopharyngeal cancer Chan et al., 2013, or (b) via vimentin
hypermethylation using methyl BEAMing for diagnosis of colon cancer
Li et al., 2009. Themost widely used serumproteinmarker for lung can-
cer, the carcino-embryonic antigen (CEA) Okamura et al., 2013 and the
best cfDNA methylation-based lung cancer assay Kneip et al., 2011,
however, do not achieve a comparable discriminative power.
In view of the increased cancer risk in ILD and COPD, and given the
lack of suitable blood tests for both diseases, we then applied our
multiplexed minimal invasive testing for identiﬁcation of ILD and
COPD. For ILD we achieved classiﬁcation results (Fig. 2C) comparable
to the of cfDNA methylation analysis in various cancer types Egger
et al., 2012. Reports on minimal invasive DNA methylation in COPD
show similar classiﬁcation rates as observed in this study, however
they concentrate on sputum samples Bruse et al., 2014, a matrix
which is not available at all times in COPD Han et al., 2010.
We then asked whether our approach was useable for differential
diagnosis of all three pulmonary diseases. We identiﬁed four top
markers (HOXD10, PAX9, PTPRN2, and STAG3) capable of effectively dis-
criminating lung cancer, ILD and COPD. Of these, PAX9 and PTPRN2 had a
particular speciﬁcity for lung cancer (Fig. 4A), whileHOXD10 and STAG3
were well-qualiﬁed to discriminate all three diseases from healthy
(Fig. 4B). To our best knowledge, changes of cfDNA methylation within
these four loci have not been reported in plasma samples of patients
with lung cancer, ILD or COPD. The results of our simulated prospective
sample classiﬁcation allow for two clinical strategies: (a) separation of
cancer from non-cancer with sensitivity of 87.8% (95%CI: 0.67–0.97)
and a speciﬁcity of 90.2%, (95%CI: 0.65–0.98), and (b) discrimination
of cancer from ILD with a speciﬁcity 88% (95%CI: 0.57–1) and from
COPD with a speciﬁcity of 88% (95%CI: 0.64–0.97) (Fig. 5). Theted resampling strategy (Supplemental Fig. S1). (A) The upper panel shows pie diagrams of
according to their clinical diagnosis. Each pie represents one patient group. Each section of
, which could not be classiﬁed to a speciﬁc disease or as healthy, because probabilities were
s. Patient 1 suffers from lung cancer; patient 2 was diagnosed with a limited UIP, patient 3
lass dependence probability for each patient. The error bar indicates the range from the cut
Fig. 6. Proof of Principle: Prospective sample prediction. ROC curve analysis of 46 patient
samples. Prediction is based on coefﬁcients derived from the model presented Fig. 3. The
dashed line represents the separation of cancer and non-cancer patients, applying a
weighted model of all 64 variables. The solid line represents the prediction based on the
top 4 markers. Panel below gives boxplots of the delta Ct-values for each marker out of
top four marker model. Due to the applied PCR methodology lower delta Ct-values indi-
cate an increased methylation of the marker.
935M. Wielscher et al. / EBioMedicine 2 (2015) 929–936classiﬁcation results further suggest that multiplexed cfDNA methyla-
tion proﬁling allows for the capture of possibly interconnected pheno-
types in spite of different clinical diagnoses. This can be deduced on
the distribution pattern across prediction probabilities from correctly
classiﬁed samples (Supplemental Fig. S12). The ﬂexibility of
multiplexed MSRE enrichment is likely to allow for the introduction of
further marker panels as well as the combination with SNP analysis im-
proving the overall diagnostic capacity of both approaches.
Moreover, plasma or serum samples, often referred to as ‘liquid bi-
opsies’ have several advantages over tissue sampling: (a) they are easily
accessible, (b) are not subject to biopsy bias Crowley et al., 2013 and
(c) can be repeatedly drawn from the same patient Dawson et al.,
2013; Thierry et al., 2014; Murtaza et al., 2013. Thus, application of
multiplexed MSRE enrichment to plasma or serum samples is ideally
suited for clinical monitoring of disease progression, particularly as
our method requires just 400 μl of plasma.
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